Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Rapamycin wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Everolimus and Rapamycin have evidence — compare verdict strength side-by-side.
No validated longevity dose. Geroscience trials used low intermittent dosing (e.g. ~0.5 mg/day or ~5 mg/week of RAD001) — unproven and not an approved regimen. Approved oncology dosing is 10 mg/day (Afinitor) and transplant dosing is trough-titrated (Zortress); both are far higher than any longevity protocol.
any
Oral everolimus tablet
No validated longevity dose. Off-label protocols use intermittent low doses (e.g. ~5–6 mg once weekly) under physician supervision — this is unproven and not an approved regimen. Approved transplant dosing is daily and immunosuppressive.
any
Oral sirolimus tablet/solution
Weeks to months
Months
Throughout use
Weeks to months
Unknown in humans
Weeks
Throughout use
Weeks to months
mTOR inhibition improves immune function in the elderly.
Science translational medicine (2014) · Rct · n=218
Randomized, placebo-controlled trial of low-dose everolimus (RAD001) in elderly volunteers
TORC1 inhibition enhances immune function and reduces infections in the elderly.
Science translational medicine (2018) · Rct · n=264
Phase 2a randomized, placebo-controlled trial in 264 elderly subjects (low-dose BEZ235 + everolimus, selective TORC1 inhibition)
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.
The lancet. Healthy longevity (2021) · Rct
Phase 2b and phase 3 (PROTECT) randomized, placebo-controlled trials of the mTOR inhibitor RTB101 in adults aged ≥65 to prevent respiratory illness
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.
Nature (2009) · Animal
NIA Interventions Testing Program study: rapamycin extended median and maximal lifespan in mice
mTOR inhibition improves immune function in the elderly.
Science translational medicine (2014) · Rct · n=218
Randomized, placebo-controlled trial of low-dose mTOR inhibition in older adults
A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs.
GeroScience (2017) · Animal · n=24
Randomized, placebo-controlled trial of short-term (10-week) low-dose rapamycin in 24 middle-aged companion DOGS (Dog Aging Project)
Rapamycin has a higher evidence score (4.5/10 vs 4.2/10) and wins in 1 of 3 categories.
No known interactions between Everolimus and Rapamycin have been documented in our database. However, always consult a healthcare provider before combining supplements.